PMID- 32938818
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201101
IS  - 1976-9148 (Print)
IS  - 2005-4483 (Electronic)
IS  - 1976-9148 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Nov 1
TI  - Diosmetin and Its Glycoside, Diosmin, Improve Atopic Dermatitis- Like Lesions in 
      2,4-Dinitrochlorobenzene-Induced Murine Models.
PG  - 542-548
LID - 10.4062/biomolther.2020.135 [doi]
AB  - Naturally derived diosmetin and its glycoside diosmin are known to be effective 
      in treating inflammatory disease. This study was performed to determine whether 
      diosmin and diosmetin have the effect of improving atopic dermatitis in a 
      2,4-dinitrochlorobenzen (DNCB)-induced atopic dermatitis (AD) model. DNCB was 
      used to establish AD model in hairless mice. Skin moisture, serum immunoglobulin 
      E (IgE), interleukin 4 (IL-4), and histological analysis were performed to 
      measure the effectiveness of diosmin and diosmetine to improve AD. IL-4 levels 
      were also measured in RBL-2H3 cells. Administration of diosmetin or diosmin 
      orally inhibited the progress of DNCB-induced AD-like lesions in murine models by 
      inhibiting transdermal water loss (TEWL) and increasing skin hydration. Diosmetin 
      or diosmin treatment also reduced IgE and IL-4 levels in AD-induced hairless 
      mouse serum samples. However, in the in vitro assay, only diosmetin, not diosmin, 
      reduced the expression level of IL-4 mRNA in RBL-2H3 cells. Diosmin and 
      diosmetine alleviated the altered epidermal thickness and immune cell 
      infiltration in AD. Diosmin is considered effective in the cure of AD and skin 
      inflammatory diseases by being converted into diosmetin in the body by 
      pharmacokinetic metabolism. Thus, oral administration of diosmetin and diosmin 
      might be a useful agent for the treatment of AD and cutaneous inflammatory 
      diseases.
FAU - Park, Sang-A
AU  - Park SA
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
FAU - Bong, Sim-Kyu
AU  - Bong SK
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
AD  - Department of Marine Food Science and Technology, Gangneung-Wonju National 
      University, Gangneung 25457, Republic of Korea.
FAU - Lee, Jin Woo
AU  - Lee JW
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
FAU - Park, No-June
AU  - Park NJ
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
FAU - Choi, Yongsoo
AU  - Choi Y
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
FAU - Kim, Sang Moo
AU  - Kim SM
AD  - Department of Marine Food Science and Technology, Gangneung-Wonju National 
      University, Gangneung 25457, Republic of Korea.
FAU - Yang, Min Hye
AU  - Yang MH
AD  - College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
FAU - Kim, Yong Kee
AU  - Kim YK
AD  - College of Pharmacy, Sookmyung Women's University, Seoul 04610, Republic of 
      Korea.
FAU - Kim, Su-Nam
AU  - Kim SN
AD  - Natural Products Research Institute, Korea Institute of Science and Technology, 
      Gangneung 25451, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Biomol Ther (Seoul)
JT  - Biomolecules & therapeutics
JID - 101472832
PMC - PMC7585636
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - DNCB
OT  - Diosmetin
OT  - Diosmin
OT  - IL-4
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest.
EDAT- 2020/09/18 06:00
MHDA- 2020/09/18 06:01
PMCR- 2020/11/01
CRDT- 2020/09/17 05:38
PHST- 2020/07/31 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/09/18 06:01 [medline]
PHST- 2020/09/17 05:38 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - biomolther.2020.135 [pii]
AID - BT-28-542 [pii]
AID - 10.4062/biomolther.2020.135 [doi]
PST - ppublish
SO  - Biomol Ther (Seoul). 2020 Nov 1;28(6):542-548. doi: 10.4062/biomolther.2020.135.